Skip to search formSkip to main contentSkip to account menu

AB 163

Known as: AB-163, bis(2,2-dimethyl-1-aziridinyl)phosphinic acid ethyl ester 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Aziridinesethyl di-(2,2-dimethyl)ethylenamido phosphate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Phase I study of ethylbis(2,2-dimethyl-1-aziridinyl)phosphinate (AB-163)
SummaryEthylbis(2,2-dimethyl-1-aziridinyl)phosphinate (AB-163) was used to treat 27 patients in a phase I trial. The limiting… 
1982
1982
A pilot study with ethyl bis (2,2-dimethyl-1-aziridinyl) phosphinate (AB-163) and radiation therapy.
1979
1979
Chemical mechanism of the radiation potentiating effects of 2,2-dimethylaziridine-type antitumor agents.
1979
1979
Radiation potentiating effect of ethyl bis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163).
1975
1975
Cyclophosphamide, 2,2-dimethylaziridines and other alkylating agents as inhibitors of serum cholinesterase.
1969
1969
Studies on the chemistry, antitumor activity, and pharmacology of ethyl Di‐(2,2 ‐dimethyl)ethylenamido phosphate (AB‐163)
AB‐163, a new alkylating agent containing the 2,2‐dimethylaziridine moiety, was found to be active against a number of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)